Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C for Complex Benign Esophageal Anastomotic Strictures
NCT04037072Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2020
- Primary completion
- Mar 2022
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitomycin c + TC-3 gel in Esophageal anastomotic stricture (EAS) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Rate of dysphagia ≥ grade 1 after the dilation procedure at 6 months. Planned start Apr 2020; status: withdrawn.
02
Drugs
mitomycin c + TC-3 gel
03
Conditions
Esophageal anastomotic stricture (EAS)
Beyond the preview
Go deeper on NCT04037072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037072.